STOCK TITAN

Intensity Therapeutics, Inc. - $INTS STOCK NEWS

Welcome to our dedicated page for Intensity Therapeutics news (Ticker: $INTS), a resource for investors and traders seeking the latest updates and insights on Intensity Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Intensity Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Intensity Therapeutics's position in the market.

Rhea-AI Summary
Intensity Therapeutics, Inc. (Nasdaq: INTS) has been selected for a spotlight oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS) on December 8, 2023. Dr. Angel Arnaout will conduct the oral presentation, highlighting the efficacy and immunomodulatory effects of INT230-6 in early-stage breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.52%
Tags
none
-
Rhea-AI Summary
Intensity Therapeutics, Inc. (INTS) presented positive Phase 1/2 clinical data for INT230-6 at the Connective Tissue Oncology Society, demonstrating a 93% disease control rate and survival extension of nearly 15 months in patients with refractory soft tissue sarcoma. The company also received Orphan Drug Designation for INT230-6 and closed an upsized IPO for $20.2 million in net proceeds. They are on track to file an IND for Phase 3 study of INT230-6 in soft tissue sarcoma and report additional Phase 2 INVICIBLE study results for presurgical breast cancer by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
-
Rhea-AI Summary
Intensity Therapeutics announces positive safety and efficacy data from Phase 1/2 clinical trial of INT230-6 in patients with sarcomas. The monotherapy showed a disease control rate of 93% and extended survival in refractory soft tissue sarcoma subjects by nearly 15 months. INT230-6 was well tolerated with 90% of adverse events being grade 1 or 2.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
Rhea-AI Summary
Intensity Therapeutics receives orphan-drug designation for soft tissue sarcoma treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
-
Rhea-AI Summary
Intensity Therapeutics, Inc. to present company overview at H.C. Wainwright 25th Annual Global Investment Conference on September 11.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
Rhea-AI Summary
Intensity Therapeutics, Inc. has priced its upsized initial public offering of 3,900,000 shares of common stock at $5.00 per share. The underwriters have been granted a 45-day option to purchase an additional 585,000 shares. Trading on The Nasdaq Capital Market under the ticker symbol 'INTS' is expected to begin on June 30, 2023. The offering is expected to close on July 5, 2023, with net proceeds of approximately $16.2 million to Intensity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Intensity Therapeutics, Inc.

Nasdaq:INTS

INTS Rankings

INTS Stock Data

67.19M
6.87M
39.13%
3.74%
0.2%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WESTPORT

About INTS

intensity therapeutics is a connecticut based biopharmaceutical company whose mission is to create safer and more efficacious chemotherapy treatments. intensity therapeutics is a preclinical, in vivo stage company seeking investors interested in helping to advance the company’s technology and products.